Literature DB >> 32886451

APOE interacts with tau PET to influence memory independently of amyloid PET in older adults without dementia.

Alexandra J Weigand1, Kelsey R Thomas2,3, Katherine J Bangen2,3, Graham M L Eglit2, Lisa Delano-Wood2,3, Paul E Gilbert4, Adam M Brickman5, Mark W Bondi2,3.   

Abstract

INTRODUCTION: Apolipoprotein E (APOE) interacts with Alzheimer's disease pathology to promote disease progression. We investigated the moderating effect of APOE on independent associations of amyloid and tau positron emission tomography (PET) with cognition.
METHODS: For 297 nondemented older adults from the Alzheimer's Disease Neuroimaging Initiative, regression equations modeled associations between cognition and (1) cortical amyloid beta (Aβ) PET levels adjusting for tau and (2) medial temporal lobe (MTL) tau PET levels adjusting for Aβ, including interactions with APOE ε4-carrier status.
RESULTS: Adjusting for tau PET, Aβ was not associated with cognition and did not interact with APOE. In contrast, adjusting for Aβ PET, MTL tau was associated with all cognitive domains. Further, there was a stronger moderating effect of APOE on MTL tau and memory associations in ε4-carriers, even among Aβ-negative individuals. DISCUSSION: Findings suggest that APOE may interact with tau independently of Aβ and that elevated MTL tau confers negative cognitive consequences in Aβ-negative ε4 carriers.
© 2020 the Alzheimer's Association.

Entities:  

Keywords:  amyloid; apolipoprotein E; cognition; memory; positron emission tomography; tau

Year:  2020        PMID: 32886451     DOI: 10.1002/alz.12173

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  11 in total

Review 1.  APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases.

Authors:  Rosalía Fernández-Calle; Sabine C Konings; Javier Frontiñán-Rubio; Juan García-Revilla; Lluís Camprubí-Ferrer; Martina Svensson; Isak Martinson; Antonio Boza-Serrano; José Luís Venero; Henrietta M Nielsen; Gunnar K Gouras; Tomas Deierborg
Journal:  Mol Neurodegener       Date:  2022-09-24       Impact factor: 18.879

Review 2.  ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease.

Authors:  Yonghe Li; Jesse R Macyczko; Chia-Chen Liu; Guojun Bu
Journal:  Neurobiol Aging       Date:  2022-03-22       Impact factor: 5.133

3.  Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer's disease.

Authors:  Vijay K Ramanan; Michael G Heckman; Timothy G Lesnick; Scott A Przybelski; Elliot J Cahn; Matthew L Kosel; Melissa E Murray; Michelle M Mielke; Hugo Botha; Jonathan Graff-Radford; David T Jones; Val J Lowe; Mary M Machulda; Clifford R Jack; David S Knopman; Ronald C Petersen; Owen A Ross; Prashanthi Vemuri
Journal:  Acta Neuropathol       Date:  2022-04-12       Impact factor: 15.887

4.  Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia.

Authors:  Chao Wang; Monica Xiong; Maud Gratuze; Xin Bao; Yang Shi; Prabhakar Sairam Andhey; Melissa Manis; Caitlin Schroeder; Zhuoran Yin; Charlotte Madore; Oleg Butovsky; Maxim Artyomov; Jason D Ulrich; David M Holtzman
Journal:  Neuron       Date:  2021-04-07       Impact factor: 17.173

5.  Association of Midlife Depressive Symptoms with Regional Amyloid-β and Tau in the Framingham Heart Study.

Authors:  Mitzi M Gonzales; Jasmeet Samra; Adrienne O'Donnell; R Scott Mackin; Joel Salinas; Mini E Jacob; Claudia L Satizabal; Hugo J Aparicio; Emma G Thibault; Justin S Sanchez; Rebecca Finney; Zoe B Rubinstein; Danielle V Mayblyum; Ron J Killiany; Charlie S Decarli; Keith A Johnson; Alexa S Beiser; Sudha Seshadri
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 6.  Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework.

Authors:  E E Wolters; A Dodich; M Boccardi; J Corre; A Drzezga; O Hansson; A Nordberg; G B Frisoni; V Garibotto; R Ossenkoppele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-06       Impact factor: 9.236

Review 7.  Functional insight into LOAD-associated microglial response genes.

Authors:  Lauren A Jonas; Tanya Jain; Yue-Ming Li
Journal:  Open Biol       Date:  2022-01-26       Impact factor: 7.124

8.  Association of APOE ɛ4 and Plasma p-tau181 with Preclinical Alzheimer's Disease and Longitudinal Change in Hippocampus Function.

Authors:  Alireza Salami; Rolf Adolfsson; Micael Andersson; Kaj Blennow; Anders Lundquist; Annelie Nordin Adolfsson; Michael Schöll; Henrik Zetterberg; Lars Nyberg
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.472

9.  Amyloid pathology but not APOE ε4 status is permissive for tau-related hippocampal dysfunction.

Authors:  Emrah Düzel; Gabriel Ziegler; David Berron; Anne Maass; Hartmut Schütze; Arturo Cardenas-Blanco; Wenzel Glanz; Coraline Metzger; Laura Dobisch; Martin Reuter; Annika Spottke; Frederic Brosseron; Klaus Fliessbach; Michael T Heneka; Christoph Laske; Oliver Peters; Josef Priller; Eike Jakob Spruth; Alfredo Ramirez; Oliver Speck; Anja Schneider; Stefan Teipel; Ingo Kilimann; Wiltfang Jens; Björn-Hendrik Schott; Lukas Preis; Daria Gref; Franziska Maier; Matthias H Munk; Nina Roy; Tomasso Ballarini; Renat Yakupov; John Dylan Haynes; Peter Dechent; Klaus Scheffler; Michael Wagner; Frank Jessen
Journal:  Brain       Date:  2022-05-24       Impact factor: 15.255

10.  The association of APOE ε4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study.

Authors:  Amin Gharbi-Meliani; Aline Dugravot; Séverine Sabia; Melina Regy; Aurore Fayosse; Alexis Schnitzler; Mika Kivimäki; Archana Singh-Manoux; Julien Dumurgier
Journal:  Alzheimers Res Ther       Date:  2021-01-04       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.